Samuel Bates Martin - 14 Jun 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP AND CFO
Signature
/s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin
Issuer symbol
CLDX
Transactions as of
14 Jun 2024
Transactions value $
-$403,325
Form type
4
Date filed
18 Jun 2024, 16:05
Previous filing
17 Jun 2024
Next filing
09 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $28.9K +3.2K +12.74% $9.02 28.3K 14 Jun 2024 Direct
transaction CLDX Common Stock Options Exercise $176K +17K +59.9% $10.38 45.3K 14 Jun 2024 Direct
transaction CLDX Common Stock Sale -$608K -17.2K -37.91% $35.42 28.1K 14 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -3.2K -100% $0.00* 0 14 Jun 2024 Common Stock 3.2K $9.02 Direct F2
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -17K -21.05% $0.00 63.6K 14 Jun 2024 Common Stock 17K $10.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.89 to $35.76 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 As of June 13, 2022, the option is fully vested.
F3 As of June 18, 2024, the option is fully vested.